Predicting treatment success for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study uses advanced testing (multi-omics) to predict if combining chemoradiation with immunotherapy works better for nasopharyngeal cancer that has returned or spread. It aims to find the right treatment for each person.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer that has come back or spread to other parts of the body.
- You are between 18 and 70 years old.
- You are able to do most daily activities without help (ECOG score 0 or 1).
- You do not have any other active cancer.
- You are not pregnant or breastfeeding.
- You understand and agree to participate by signing a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests a chemotherapy plan for people whose nasopharyngeal cancer has come back locally (T3/T4). It aims to see if treatment given after return of cancer can help control the disease without spreading to distant organs.
This study looks at special blood markers (CTCs) to see how sensitive your cancer is to chemotherapy and to better predict how well treatment may work. If you have metastatic nasopharyngeal cancer and can’t have local treatment, this may help match you to more effective chemo plans.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
This trial compares two treatment options for people with nasopharyngeal cancer that did not respond well to initial chemotherapy. One option is to switch to a different chemotherapy regimen, the other is to go straight to radiation therapy. The study aims to see which approach is more effective in this situation.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.